Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

Pohl, G; Rudas, M; Dietze, O; Lax, S; Markis, E; Pirker, R; Zielinski, CC; Hausmaninger, H; Kubista, E; Samonigg, H; Jakesz, R; Filipits, M.
High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin.
J Clin Oncol. 2003; 21(19):3594-3600 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Autor/innen der Med Uni Graz:
Samonigg Hellmut
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
PURPOSE: To determine the predictive value of p27Kip1 in premenopausal women with early-stage hormone receptor-positive breast cancer. PATIENTS AND METHODS: We retrospectively examined tumor specimens from 512 patients with breast cancer who were enrolled onto Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 5. In this trial, premenopausal, hormone receptor-positive breast cancer patients with stage I and II disease were randomly assigned to receive either 5 years of tamoxifen plus 3 years of goserelin or six cycles of cyclophosphamide, methotrexate, and fluorouracil. p27Kip1 expression was assessed by immunohistochemistry, and its association with clinical outcome was determined. Statistical analyses were performed to test for interaction between p27Kip1 status and treatment. RESULTS: High p27Kip1 expression (nuclear p27Kip1 staining in >/= 50% of tumor cells) independently predicted superior relapse-free survival (RFS) and overall survival (OS) in both the total study population (RFS: relative risk [RR], 0.53; 95% CI, 0.34 to 0.82; P =.004; OS: RR, 0.29; 95% CI, 0.15 to 0.58; P <.001) and patients treated with combination endocrine therapy (RFS: RR, 0.32; 95% CI, 0.16 to 0.63; P =.001; OS: RR, 0.16; 95% CI, 0.05 to 0.53; P =.003). The interaction between p27Kip1 expression and treatment was statistically significant for RFS (P =.04) but not for OS (P =.27). CONCLUSION: High p27Kip1 expression was an independent predictor of responsiveness to hormonal therapy and thus may be useful for the selection of premenopausal women with early-stage hormone receptor-positive breast cancer for adjuvant combination endocrine therapy.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Antineoplastic Agents, Hormonal - administration and dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast Neoplasms - drug therapy
Cell Cycle Proteins - biosynthesis
Cyclin-Dependent Kinase Inhibitor p27 - biosynthesis
Cyclin-Dependent Kinases - antagonists and inhibitors
Disease-Free Survival - antagonists and inhibitors
Female - antagonists and inhibitors
Gene Expression Regulation, Neoplastic - antagonists and inhibitors
Genes, Tumor Suppressor - antagonists and inhibitors
Goserelin - administration and dosage
Humans - administration and dosage
Immunohistochemistry - administration and dosage
Middle Aged - administration and dosage
Predictive Value of Tests - administration and dosage
Prognosis - administration and dosage
Retrospective Studies - administration and dosage
Tamoxifen - therapeutic use
Treatment Outcome - therapeutic use
Tumor Suppressor Proteins - biosynthesis

© Meduni Graz Impressum